|
Cardiovascular Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Since its discovery in 1999, studies have shown the involvement of GDF11 in normal physiological processes, such as embryonic development and erythropoiesis, as well as in the pathophysiology of aging, cardiovascular disease, diabetes mellitus, and cancer.
|
29113418 |
2017 |
|
Cardiovascular Diseases
|
0.030 |
AlteredExpression
|
group |
BEFREE |
The latest studies have shown that the level of circulating GDF 11 correlates with the outcomes of patients with cardiovascular diseases, cancer and uremia.
|
28223232 |
2017 |
|
Cardiovascular Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Administration of GDF11 may be an efficacious therapy to protect against cardiovascular diseases in splenectomized patients.
|
27565745 |
2017 |
|
Chronic Obstructive Airway Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
Decrease in an anti-ageing factor, growth differentiation factor 11, in chronic obstructive pulmonary disease.
|
28455454 |
2017 |
|
Myocardial Infarction
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Young (3 months) and old (21 months) mice were used to evaluate the expression of GDF11 mRNA in the myocardium at baseline and after ischemia/reperfusion (I/R) and myocardial infarction.
|
28004242 |
2017 |
|
Obesity
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
We firstly confirmed that the expression of GDF11 decreased both in the skeletal muscle of obese mice and palmitate-treated myotubes, but supplementation GDF11 does not ameliorate the palmitate-induced insulin resistance in C2C12 myotubes.
|
28485800 |
2017 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Since its discovery in 1999, studies have shown the involvement of GDF11 in normal physiological processes, such as embryonic development and erythropoiesis, as well as in the pathophysiology of aging, cardiovascular disease, diabetes mellitus, and cancer.
|
29113418 |
2017 |
|
Alzheimer's Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
We suggest that alterations of GDF11 and Tregs are involved in AD progression and that rejuvenation of the immune system is a potential therapeutic strategy in AD.
|
26317549 |
2015 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Quantitative real-time reverse transcription-PCR in colorectal cancer specimens obtained from 130 patients showed that GDF11 mRNA expression in cancer tissue was significantly higher than in normal tissue (p=0.001).
|
17912435 |
2007 |
|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Although multivariate analysis showed that GDF11 was not an independent prognostic factor, these findings suggest that GDF11 may be a novel diagnostic and prognostic biomarker in patients with colorectal cancer.
|
17912435 |
2007 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Quantitative real-time reverse transcription-PCR in colorectal cancer specimens obtained from 130 patients showed that GDF11 mRNA expression in cancer tissue was significantly higher than in normal tissue (p=0.001).
|
17912435 |
2007 |
|
Malignant neoplasm of colon and/or rectum
|
0.030 |
Biomarker
|
disease |
BEFREE |
Although multivariate analysis showed that GDF11 was not an independent prognostic factor, these findings suggest that GDF11 may be a novel diagnostic and prognostic biomarker in patients with colorectal cancer.
|
17912435 |
2007 |
|
Metabolic Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
As such, GDF11 could be considered as an important therapeutic candidate for age-related neurodegenerative and metabolic disorders.
|
31637864 |
2020 |
|
Anemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
This suggests an impaired GDF11 response contributing to anemia in AA patients.
|
30727851 |
2019 |
|
Anemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Prior studies suggested that inhibition of growth differentiation factor 11 (GDF11) through soluble activin receptor type II (ActRII) ligand traps or neutralizing antibodies promotes erythroid precursor cell maturation and red blood cell formation in contexts of homeostasis and anemia.
|
31530563 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Circulating GDF11 levels are decreased with age but are unchanged with obesity and type 2 diabetes.
|
30897065 |
2019 |
|
Heart failure
|
0.020 |
Biomarker
|
disease |
BEFREE |
Growth differentiation factor 11 is involved in isoproterenol‑induced heart failure.
|
30942402 |
2019 |
|
Heart failure
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Recently, targeted myocardial delivery of the GDF11 gene in aged mice was found to reduce heart failure and enhance the proliferation of cardiac progenitor cells after myocardial ischemia-reperfusion (I-R).
|
30900023 |
2019 |
|
Congestive heart failure
|
0.020 |
Biomarker
|
disease |
BEFREE |
Growth differentiation factor 11 is involved in isoproterenol‑induced heart failure.
|
30942402 |
2019 |
|
Congestive heart failure
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Recently, targeted myocardial delivery of the GDF11 gene in aged mice was found to reduce heart failure and enhance the proliferation of cardiac progenitor cells after myocardial ischemia-reperfusion (I-R).
|
30900023 |
2019 |
|
Metabolic Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
These results demonstrate that GDF11 plays an important role in regulating metabolic homeostasis and energy balance and could be a target for pharmacological intervention to treat metabolic disease.
|
31847906 |
2019 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Finally, in vivo invasion studies revealed a significant decrease in cell migration of hepatocellular carcinoma cells treated with GDF11 associated to a decreased proliferation judged by Ki67 staining.
|
30890427 |
2019 |
|
Liver regeneration disorder
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Treatment with adeno-associated viruses-GDF11 and recombinant GDF11 protein severely impaired liver regeneration, whereas inhibition of GDF11 activity with neutralizing antibodies significantly improved liver regeneration after PH.
|
31654062 |
2019 |
|
MYELODYSPLASTIC SYNDROME
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Luspatercept (and sotatercept), ligand traps that particularly inhibit GDF11, lead to RBC transfusion independence in 10% to 50% of lower-risk MDSs resistant to available treatments, and have started to be used in PMF.
|
30602619 |
2019 |
|
Arteriosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Growth differentiation factor 11 (GDF11) has an anti-inflammatory effect in the mouse model of atherosclerosis and Alzheimer's disease, but how GDF11 regulates intestinal inflammation during ulcerative colitis (UC) is poorly defined.
|
30188752 |
2018 |